GSK2879552

GSK2879552

Catalog Number:
L002371307APE
Mfr. No.:
APE-B5879
Price:
$262
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Description:
          EC50: 38 nM for anti-proliferative growth effect in 19 of 25 AML cell lines
          Lysine specific demethylase 1 (LSD1) is a histone H3K4me1/2 demethylase found in various transcriptional co-repressor complexes. LSD1 can interact with pluripotency factors in human embryonic stem cells and is important for decommissioning enhancers in stem cell differentiation. LSD1 is overexpressed in multiple cancer types and recent studies suggest inhibition of LSD1 reactivates the all-trans retinoic acid receptor pathway in acute myeloid leukemia (AML). GSK2879552 is a novel and irreversible LSD1 inhibitor.
          In vitro: Six days of GSK2879552 treatment resulted in potent anti-proliferative growth effects in 19 of 25 AML cell lines representing a range of AML subtypes. Treating for longer time periods revealed sensitivity in all AML cell lines. AML blast colony forming ability was also inhibited in 4 of 5 bone marrow samples derived from primary AML patient samples [1].
          In vivo: After 17 days of GSK2879552 treatment, control mice had 80% GFP+ cells in the bone marrow whereas treated mice had only 2.8% GFP positive cells, and the treated animals survived weeks beyond control mice [1].
          Clinical trial: A phase I, open-label, multi-center, non-randomized, 2-part first time in human (FTIH) study for GSK2879552 has been condcuted to investigate the effect of GSK2879552 in subjects with relapsed/refractory small cell lung carcinoma.

      • Properties
        • Alternative Name
          4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid
          CAS Number
          1401966-69-5
          Molecular Formula
          C23H28N2O2
          Molecular Weight
          364.48
          Appearance
          A solid
          Purity
          98.70%
          Solubility
          insoluble in EtOH; ≥10.14 mg/mL in H2O with ultrasonic; ≥12.8 mg/mL in DMSO
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Bhattacharya U, Gutter-Kapon L, et al. "Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth. "Cancer Res. 2020 Jan 1;80(1):57-68. PMID:31690669
          2.Hoang N, Zhang X, et al. "New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells." Bioorg Med Chem. 2018 Feb 7. pii: S0968-0896(17)31942-9. PMID:29439916

    We Also Recommend

    ORY-1001

    $292

    RI-2

    $438

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.